Peripheral Blood Biomarkers for Rheumatoid Arthritis–Associated Interstitial Lung Disease: A Systematic Review

Background Biomarkers have been proposed as tools to aid in the identification and prognostication of interstitial lung disease (ILD) in rheumatoid arthritis (RA). We performed a systematic review of studies evaluating peripheral blood biomarkers and their association with RA‐ILD and its prognosis....

Full description

Saved in:
Bibliographic Details
Published inACR open rheumatology Vol. 5; no. 4; pp. 201 - 226
Main Authors Van Kalsbeek, Daniel, Brooks, Rebecca, Shaver, Dawson, Ebel, Ariadne, Hershberger, Daniel, Schmidt, Cynthia, Poole, Jill A., Ascherman, Dana P., Thiele, Geoffrey M., Mikuls, Ted R., England, Bryant R.
Format Journal Article
LanguageEnglish
Published Boston, USA Wiley Periodicals, Inc 01.04.2023
John Wiley & Sons, Inc
Wiley
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Background Biomarkers have been proposed as tools to aid in the identification and prognostication of interstitial lung disease (ILD) in rheumatoid arthritis (RA). We performed a systematic review of studies evaluating peripheral blood biomarkers and their association with RA‐ILD and its prognosis. Methods Medline, Embase, the Cochrane Library, and Scopus were queried for relevant studies, with the final search update on July 12, 2021. We included studies evaluating peripheral blood biomarkers for the identification and/or prognostication of RA‐ILD, extracting the performance of individual biomarkers for identifying RA‐ILD, and predicting prognosis. Modified versions of the Quality Assessment of Diagnostic Accuracy Studies 2 and the Quality in Prognosis Studies tools were used for quality assessment. Results Seventy studies met eligibility criteria. Study and patient characteristics, analytical methods, strength and consistency of associations, and study quality were heterogeneous. A total of 92 biomarkers were positively associated and 12 were negatively associated with RA‐ILD among patients with RA in one or more report. Only a small number of biomarkers were evaluated in multiple cohorts using adjusted analyses. Biomarkers most strongly associated with RA‐ILD overlapped with those identified for idiopathic pulmonary fibrosis. Few prognostic biomarkers of RA‐ILD were identified. Conclusion Several peripheral blood biomarkers are associated with the presence of RA‐ILD, but few have been assessed in multivariable models, have been externally validated, have discriminated RA‐ILD from other lung disease, or have prognosticated the disease course. High‐quality studies investigating and validating peripheral biomarkers in RA‐ILD are needed before they can be employed in clinical care.
Bibliography:There was no funding directly supporting the conduct of this study. The authors disclose the following funding support: Dr. Poole's work was supported by the Department of Defense (PR200793) and the National Institute for Occupational Safety and Health (R01‐OH‐012045 and U54‐OH‐010162). Dr. Mikuls's work was supported by the VA Biomedical Laboratory Research and Development (I01 BX004660), the Department of Defense (PR200793), the Rheumatology Research Foundation, and the National Institute of General Medical Sciences (U54‐GM‐115458). Dr. England's work was supported by the VA Clinical Science Research and Development (IK2 CX002203), the Rheumatology Research Foundation, and the National Institute of General Medical Sciences (U54‐GM‐115458), which funds the Great Plains Institutional Development Award for Clinical and Translational Research Network.
https://onlinelibrary.wiley.com/action/downloadSupplement?doi=10.1002%2Facr2.11535&file=acr211535‐sup‐0001‐Disclosureform.pdf
The views expressed herein are those of the authors and do not necessarily represent the position or policy of the Department of Veterans Affairs or the US Government.
.
PROSPERO identifier: CRD42019137143.
Author disclosures are available at
ObjectType-Article-2
SourceType-Scholarly Journals-1
content type line 14
ObjectType-Feature-3
ObjectType-Evidence Based Healthcare-1
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
Author disclosures are available at https://onlinelibrary.wiley.com/action/downloadSupplement?doi=10.1002%2Facr2.11535&file=acr211535‐sup‐0001‐Disclosureform.pdf.
ISSN:2578-5745
2578-5745
DOI:10.1002/acr2.11535